These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 34708593)

  • 21. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.
    Arbyn M; Ronco G; Anttila A; Meijer CJ; Poljak M; Ogilvie G; Koliopoulos G; Naucler P; Sankaranarayanan R; Peto J
    Vaccine; 2012 Nov; 30 Suppl 5():F88-99. PubMed ID: 23199969
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical performance of human papillomavirus based cervical cancer screening algorithm: The result of a large Danish implementation study.
    Lindquist S; Kjær SK; Frederiksen K; Ørnskov D; Petersen LK; Munk C; Waldstrøm M
    Acta Obstet Gynecol Scand; 2024 Sep; 103(9):1781-1788. PubMed ID: 39012789
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HPV16 and HPV18 genotyping triage in young women with borderline cytology or mild dyskaryosis: effect of age on genotype-specific risk of high-grade CIN.
    McKenna M; McMenamin M; McDowell A
    Cytopathology; 2016 Aug; 27(4):261-8. PubMed ID: 26873051
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Primary screening for cervical cancer based on high-risk human papillomavirus (HPV) detection and HPV 16 and HPV 18 genotyping, in comparison to cytology.
    Agorastos T; Chatzistamatiou K; Katsamagkas T; Koliopoulos G; Daponte A; Constantinidis T; Constantinidis TC;
    PLoS One; 2015; 10(3):e0119755. PubMed ID: 25793281
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of a validated methylation triage signature for human papillomavirus positive women in the HPV FOCAL cervical cancer screening trial.
    Cook DA; Krajden M; Brentnall AR; Gondara L; Chan T; Law JH; Smith LW; van Niekerk DJ; Ogilvie GS; Coldman AJ; Warman R; Reuter C; Cuzick J; Lorincz AT
    Int J Cancer; 2019 May; 144(10):2587-2595. PubMed ID: 30412281
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of HPV-16 and HPV-18 Genotyping and Cytological Testing as Triage Testing Within Human Papillomavirus-Based Screening in Mexico.
    Torres-Ibarra L; Cuzick J; Lorincz AT; Spiegelman D; Lazcano-Ponce E; Franco EL; Moscicki AB; Mahmud SM; Wheeler CM; Rivera-Paredez B; Hernández-López R; León-Maldonado L; Salmerón J;
    JAMA Netw Open; 2019 Nov; 2(11):e1915781. PubMed ID: 31747033
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk stratification for cervical precancer and cancer by DH3-HPV partial genotyping and cytology in women attending cervical screening: A retrospective cohort study.
    Fu Y; Li Y; Li X; Wang X; Lü W
    J Med Virol; 2023 Feb; 95(2):e28482. PubMed ID: 36609841
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Protocol for Compass: a randomised controlled trial of primary HPV testing versus cytology screening for cervical cancer in HPV-unvaccinated and vaccinated women aged 25-69 years living in Australia.
    Canfell K; Saville M; Caruana M; Gebski V; Darlington-Brown J; Brotherton J; Heley S; Castle PE
    BMJ Open; 2018 Jan; 8(1):e016700. PubMed ID: 29374658
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Extended Human Papillomavirus Genotyping to Predict Progression to High-Grade Cervical Precancer: A Prospective Cohort Study in the Southeastern United States.
    Bukowski A; Hoyo C; Hudgens MG; Brewster WR; Valea F; Bentley RC; Vidal AC; Maguire RL; Schmitt JW; Murphy SK; North KE; Smith JS
    Cancer Epidemiol Biomarkers Prev; 2022 Aug; 31(8):1564-1571. PubMed ID: 35654413
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Triage of HPV-positive women in Norway using cytology, HPV16/18 genotyping and HPV persistence.
    Arbyn M; Rezhake R; Yuill S; Canfell K
    Br J Cancer; 2020 May; 122(11):1577-1579. PubMed ID: 32242099
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cervical Precancer and Cancer Risk by Human Papillomavirus Status and Cytologic Interpretation: Implications for Risk-Based Management.
    Castle PE; Aslam S; Behrens C
    Cancer Epidemiol Biomarkers Prev; 2016 Dec; 25(12):1595-1599. PubMed ID: 27587789
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk stratification of HPV-positive results using extended genotyping and cytology: Data from the baseline phase of the Onclarity trial.
    Stoler MH; Parvu V; Yanson K; Andrews J; Vaughan L
    Gynecol Oncol; 2023 Jul; 174():68-75. PubMed ID: 37149907
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Detection of high-grade cervical neoplasia using extended genotyping: Performance data from the longitudinal phase of the Onclarity trial.
    Stoler MH; Wright TC; Parvu V; Yanson K; Cooper CK; Andrews JA
    Gynecol Oncol; 2023 Mar; 170():143-152. PubMed ID: 36682092
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effective methylation triage of HPV positive women with abnormal cytology in a middle-income country.
    Ramírez AT; Sánchez GI; Nedjai B; Agudelo MC; Brentnall AR; Cuschieri K; Castañeda KM; Cuzick J; Lorincz AT;
    Int J Cancer; 2021 Mar; 148(6):1383-1393. PubMed ID: 33006394
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Performance of standardised colposcopy to detect cervical precancer and cancer for triage of women testing positive for human papillomavirus: results from the ESTAMPA multicentric screening study.
    Valls J; Baena A; Venegas G; Celis M; González M; Sosa C; Santin JL; Ortega M; Soilán A; Turcios E; Figueroa J; Rodríguez de la Peña M; Figueredo A; Beracochea AV; Pérez N; Martínez-Better J; Lora O; Jiménez JY; Giménez D; Fleider L; Salgado Y; Martínez S; Bellido-Fuentes Y; Flores B; Tatti S; Villagra V; Cruz-Valdez A; Terán C; Sánchez GI; Rodríguez G; Picconi MA; Ferrera A; Mendoza L; Calderón A; Murillo R; Wiesner C; Broutet N; Luciani S; Pérez C; Darragh TM; Jerónimo J; Herrero R; Almonte M;
    Lancet Glob Health; 2023 Mar; 11(3):e350-e360. PubMed ID: 36796982
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Age-specific effectiveness of primary human papillomavirus screening versus cytology in a cervical cancer screening program: a nationwide cross-sectional study.
    Bao H; Ma L; Zhao Y; Song B; Di J; Wang L; Gao Y; Ren W; Wang S; Wu J; Wang HJ
    Cancer Commun (Lond); 2022 Mar; 42(3):191-204. PubMed ID: 35142100
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The impact of human papillomavirus genotype on colposcopic appearance: a cross-sectional analysis.
    van der Marel J; van Baars R; Quint WG; Berkhof J; del Pino M; Torné A; Ordi J; Wentzensen N; Schiffman M; van de Sandt MM; Lindeman J; Jenkins D; Helmerhorst TJ; Verheijen RH; ter Harmsel B; Alonso I
    BJOG; 2014 Aug; 121(9):1117-26. PubMed ID: 24494663
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparing triage algorithms using HPV DNA genotyping, HPV E7 mRNA detection and cytology in high-risk HPV DNA-positive women.
    Luttmer R; Berkhof J; Dijkstra MG; van Kemenade FJ; Snijders PJ; Heideman DA; Meijer CJ
    J Clin Virol; 2015 Jun; 67():59-66. PubMed ID: 25959161
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Human papillomavirus E7 protein detection as a method of triage to colposcopy of HPV positive women, in comparison to genotyping and cytology. Final results of the PIPAVIR study.
    Agorastos T; Chatzistamatiou K; Moysiadis T; Kaufmann AM; Skenderi A; Lekka I; Koch I; Soutschek E; Boecher O; Kilintzis V; Angelidou S; Katsiki E; Hagemann I; Boschetti Gruetzmacher E; Tsertanidou A; Angelis L; Maglaveras N; Jansen-Duerr P
    Int J Cancer; 2017 Aug; 141(3):519-530. PubMed ID: 28470689
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical efficacy of primary human papillomavirus (HPV) screening with partial genotyping for HPV-16 and HPV-18 subtypes in women from 25 years old.
    Ang JX; Lee WY; Tay SK
    Ann Acad Med Singap; 2023 May; 52(5):259-267. PubMed ID: 38904523
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.